Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Fineline Cube Mar 31, 2026
Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Fineline Cube Mar 31, 2026
Company Drug

EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review

Fineline Cube Feb 13, 2023

EOC Pharma, a biotech operating out of the US and China, has announced that a...

Company Drug

Joincare’s Generic Seretide Accepted for NMPA Review

Fineline Cube Feb 10, 2023

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...

Company Deals

Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs

Fineline Cube Feb 10, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...

Company Drug

Everest Medicines’ Nefecon Included in South Korea’s GIFT Program

Fineline Cube Feb 10, 2023

China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...

Company Deals

Haohai Bio Acquires Additional Stake in SZNIMO for Ophthalmic Expansion

Fineline Cube Feb 10, 2023

China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366), a leading biomaterial firm...

Company Drug

Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors

Fineline Cube Feb 10, 2023

China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its...

Company

AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth

Fineline Cube Feb 10, 2023

UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4...

Company Drug

Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval

Fineline Cube Feb 9, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...

Company Deals

Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board

Fineline Cube Feb 9, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...

Company Deals

Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions

Fineline Cube Feb 9, 2023

China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation,...

Company Deals

GenScript ProBio Partners with Bio Immunitas for hRPP Platform

Fineline Cube Feb 9, 2023

Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a...

Company Drug

ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment

Fineline Cube Feb 9, 2023

Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011...

Company Deals

Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs

Fineline Cube Feb 9, 2023

China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...

Company Deals

Neurodawn Completes Series A+ Financing for CNS Drug Development

Fineline Cube Feb 9, 2023

Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has...

Company Drug

Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study

Fineline Cube Feb 9, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...

Company Deals

Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering

Fineline Cube Feb 9, 2023

Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional...

Company Deals

Teddy Clinical Research Lab Partners with Cerba Research for Global Services

Fineline Cube Feb 9, 2023

China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244)...

Company Deals

Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma

Fineline Cube Feb 8, 2023

Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...

Company Deals

Macrolux Secures Series A Funding for Endoscopy Solutions

Fineline Cube Feb 8, 2023

Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB...

Company Deals

Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin

Fineline Cube Feb 8, 2023

China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...

Posts pagination

1 … 542 543 544 … 643

Recent updates

  • AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
  • Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
  • NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma
  • Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway
  • Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Medical Device

Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety

Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.